期刊文献+

Her-2/neu基因过表达与胃癌生物学行为的关系研究 被引量:4

Relationship between the overexpression of Her-2/neu gene and biologic behavior of human gastric carcinoma
下载PDF
导出
摘要 目的:了解Her-2/neu基因过表达与胃癌生物学行为的关系。方法:应用免疫组化法检测了具有随访资料的164例胃癌标本的Her-2/neu基因的表达状态。结果:164例胃癌的Her-2/neu基因过表达率为19·51%,其过表达与患者的性别、年龄、肿瘤生长的部位、分化程度、浸润深度、脉管内癌细胞的浸润、UICC分期均无关(P>0·05);仅与胃癌的病理类型密切相关(P<0·05);且Her-2/neu基因过表达与胃癌的预后无关,胃癌的预后仅与胃癌的浸润深度和UICC分期有关。结论:胃癌Her-2/neu基因过表达似与胃癌的病理类型密切相关,预后与肿瘤的浸润深度和UICC分期有关。 Objective:To learn the relationship between the overexpression of Her-2/neu gene and biologic behavior of human gastric carcinoma. Methods:Overexpression of Her-2/neu gene in 164 follow-up cases of human gastric carcinoma specimens were detected by immunhistochemistry. Results:The overexpression incidence of Her-2/neu gene in these specimens was 19. 51% ,the overexpression didn't show a significant correlation to patients'sex age, location of the carcinoma, infiltration depth, differentiated degree, infiltration of carcinoma cells in vessels and UICC staging. (P 〉 0. 05 ), only has a closely relationship with the pathological type of gastric carcinoma. ( P 〈 0. 05 ) ;while overexpression of Her-2/neu gene was irrelated to prognosis of gastric carcinoma. The prognosis was related to the infiltration of carcinoma and the UICC staging. Conclusion:The overexpression of Her-2/neu gene in gastric carcinoma has a closely relationship with the pathologic type of gastric carcinoma,the prognosis of gastric carcinoma was related to the infiltration depth and UICC stsging.
出处 《临床肿瘤学杂志》 CAS 2006年第2期105-109,共5页 Chinese Clinical Oncology
关键词 胃癌 HER-2/NEU基因 生物学行为 Gastric carcinoma Her-2/neu gene Biologic behavior
  • 相关文献

参考文献8

二级参考文献15

共引文献37

同被引文献36

  • 1陈斌,罗荣城,崔斐,钱新宇.胃癌HER-2/neu基因表达与预后的相关性[J].南方医科大学学报,2006,26(3):344-347. 被引量:44
  • 2黄悦,赵建华,樊克武.CD147及MMP-2在胃癌中的表达及意义[J].肿瘤基础与临床,2007,20(1):21-23. 被引量:3
  • 3Ardavanis A,Kountourakis P,Kyriakou F,et al.Trastuzumab plus Paclitaxel or Docetaxel in Her-2–Negative/Her-2 ECD–Positive Anthracycline-and Taxane-Refractory Advanced Breast Cancer[J].Oncologist,2008,13:361-9.
  • 4Thureau S,Clatot F,Pillé J,et al.Prognostic value of serum level of HER-2 extracellular domain (ECD) at diagnosis of Her-2 overexpressed primary breast cancer (BC)[J].ASCO Meeting Abstracts,2009,27:e1150.
  • 5Meza-Junco J,Au HJ,Sawyer MB.Trastuzumab for gastric cancer.Cross Cancer Institute[J].Medical Oncology,Edmonton,Alberta,Canada,2009,9(12):1543-51.
  • 6Marx AH,Tharun L,Muth J,et al.Her-2 amplification is highly homogenous in gastric cancer[J].Hum Pathol,2010,41(2):304-6.
  • 7Watanabe N,Miyamoto M,Tokuda Y,et al.Serum c-cerbB-2 inbreast cancer patients[J].Acta Oncol,1994,33(8):901-4.
  • 8Ilson DH. Esophageal cancer chemotherapy: recent advances[J]. Gastrointest Cancer Res,2008,2(2) : 85-92.
  • 9Novotny AR, Schuhmacher C, Busch R,et al. Predictinga U. S. -derived nomogram at a single high-volume center inEurope[J]. Ann Surg,2006,243(1):74-81.
  • 10Van Cutsem E, Kang Y, Chung HC, et al. Efficacy resultsfrom the ToGA trial; a phase DI study of trastuzumab addedto standard chemotherapy(CT) in first-line human epidermalgrowth factor receptor 2 ( HER2 )-positive advancedgastriccancer(GC)[J]. J Clin Oncol,2009,27(18 Suppl) :LBA4509.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部